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Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients
for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the
protein determined by immunohistochemistry (IHC) are the two major methods to establish this status. A strong correlation has
been previously demonstrated between these two methods. However, FISH is not always feasible in routine practice and weakly
positive IHC tumours (2þ) do not always correspond to a gene amplification. Our study was performed in order to evaluate the
contribution of chromogenic in situ hybridisation (CISH), which enables detection of the gene copies through an immunoperoxidase
reaction. CISH was performed in 79 breast carcinomas for which the HER2 status was previously determined by IHC and FISH. The
results of IHC, FISH and CISH were compared for each tumour. CISH procedures were successful in 95% of our cases. Whatever the
IHC results, we found a very good concordance (96%) between CISH and FISH. Our study confirms that CISH may be an alternative
to FISH for the determination of the gene amplification status in 2þ tumours. Our results allow us to think that, in many laboratories,
CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC
signal is in agreement with the gene status.
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Determination of HER2 status has now become of major clinical
importance with the advent of anti-HER2 therapy, the recombi-
nant humanised anti-p185
Her-2/neu antibody trastuzumab (Hercep-
tin
s) (Pegram et al, 1998; Cobleigh et al, 1999; Slamon et al, 2001).
Immunohistochemistry (IHC) is expected to be the best method
for the determination of HER2 status, as IHC assesses the level of
HER2 overexpression, which is the target of Herceptin
s therapy.
Moreover, the patient’s selection for Herceptin
s therapy is mainly
based on IHC because previous studies demonstrated a good
correlation between IHC results and gene status, as determined by
fluorescence in situ hybridisation (FISH) (Pegram et al, 1998;
Jacobs et al, 1999, 2000; Couturier et al, 2000; Jimenez et al, 2000;
Lebeau et al, 2001; Lehr et al, 2001). However, the HER2-IHC
detection was criticised because of a lack of interlaboratory
reproducibility and, furthermore, Herceptest
s, a standardised IHC
method, was shown to be a method with excessive sensitivity when
compared to FISH (Persons et al, 1997; Bartlett et al, 2001; Tubbs
et al, 2001). Even though HER2 overexpression without gene
amplification was reported in 2.9–8.3% of cases (Kallioniemi et al,
1992; Persons et al, 1997; Couturier et al, 2000; Jimenez et al, 2000;
Pauletti et al, 2000), discordant results between IHC and FISH were
mainly observed for tumours that were scored 2þ by IHC (Persons
et al, 1997; Bartlett et al, 2001; Tubbs et al, 2001). For this reason,
and particularly in Europe, a confirmation of HER2 gene
amplification by FISH became mandatory for a patient’s inclusion
in a clinical trial using Herceptin
s, when the corresponding
tumour is scored 2þ by IHC (Hoang et al, 2000; Ridolfi et al, 2000;
Diaz, 2001; Tubbs et al, 2001; Vogel et al, 2002).
Some authors found that HER2 status determined by FISH was
more reproducible (Press et al, 1994; Persons et al, 1997; Bartlett
et al, 2001; Tubbs et al, 2001). Thus, these authors thought that
FISH had to be proposed as the only method to select patients for
Herceptin
s. However, FISH is a long and expensive procedure that
requires trained personnel and fluorescence microscopy.
Chromogenic in situ hybridisation (CISH) is a recently
introduced technique in which the DNA probe is detected using
an immunoperoxidase reaction (Tanner et al, 2000). This method
is very close to FISH but does not require the use of fluorescence
microscopy. Moreover, FISH signals fade within a few weeks and
the FISH results have to be recorded with expensive digital
systems. This is not the case for CISH staining. Owing to the
similarity with IHC staining, CISH is also easier to interpret for
pathologists who are not trained with fluorescence. In one study
(Tanner et al, 2000), CISH was demonstrated to be well correlated
with FISH.
The aims of our study were to: (a) confirm the good correlation
between FISH and CISH in a nonhomogeneous series of breast
tumours coming from eight different laboratories using different Received 4 July 2002; revised 31 January 2003; accepted 5 March 2003
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sfixation procedures, (b) analyse this correlation according to the
expression of HER2 protein analysed by IHC (c) focus on IHC 2þ
cases and analyse in this situation if CISH gives the same
information as FISH for the treatment of patients.
MATERIALS AND METHODS
Tumours
A total of 79 tumours were collected from eight French
laboratories. Each laboratory selected cases in which IHC and
FISH were previously and successfully performed. In order to
analyse the discriminating power of CISH in difficult cases,
tumours scored as 2þ by IHC were chosen in priority for this
study. Owing to differences in the fixative procedure between the
laboratories, 47 tumours were fixed in neutral-buffered formalin,
10 in Holland’s bouin, and 22 in alcohol–formalin–acetic acid
(AFA).
IHC
The monoclonal antibody CB11 (Novocastra, Newcastle, England)
was used in 25 cases and the polyclonal antibody A485 (Dako,
Glostrup, Denmark) in 44 cases. For all slides, immunostaining
was scored according to the Herceptest
s scoring system, which is
also used in clinical trials (Cobleigh et al, 1999; Slamon et al, 2001).
Negativity of normal glands was the prerequisite for interpreting
the cases, according to the recommendations of the College of
American Pathologists (Fitzgibbons et al, 2000).
FISH
FISH was performed in three different referent laboratories. It was
performed on frozen tumour sections in 65 cases and on fixed-
paraffin-embedded samples in the 14 remaining cases. FISH
experiments were performed according to the protocol given by
the supplier (PathVysion kit, Vysis, Downers Grove, IL or Ventana
HER2 inform, Tucson, AZ). The centromeric probe of chromo-
some 17 was included in FISH analyses in 62 cases. In these 62
cases, HER2 amplification was determined as a ratio of HER2 and
chromosome 17 centromere signal counts. As in the study
previously published (Tanner et al, 2000), ratios o2 were
determined as no amplification with FISH (NAF) (Figure 1B),
those between 2 and 5 as low-level amplification with FISH (LAF)
(Figure 1D) and those 45 as high-level amplification with FISH
(HAF) (Figure 1F). In the 14 other cases, without centromeric 17
analysis, like for the CISH analysis in the study previously
published (Tanner et al, 2000), HER2 gene was judged as NAF
when 1–5 signals were present per nucleus. When 6–10 signals
were present in more than 50% of tumour cell nuclei, the tumours
were judged as LAF. Finally, tumours having more than 10 signals
in more than 50% of the nuclei were judged as HAF.
CISH
CISH experiments were performed according to the protocol given
by the supplier (Zymed Inc., South San Francisco, CA, USA). The
interpretation of the signal was that used by other authors (Tanner
et al, 2000) and was only performed on invasive tumour patterns.
HER2 gene was judged as nonamplified with CISH (NAC) when
1–5 signals were present per nucleus (Figure 1A).When 6–10
signals were present in more than 50% of tumour cell nuclei, the
tumours were judged as having a low level of amplification with
CISH (LAC) (Figure 1C). Finally, the tumours with more than 10
signals or with large gene copy clusters in more than 50% of the
nuclei were judged as having a high level of HER2 gene
amplification (HAC) (Figure 1E).
RESULTS
Evaluation of IHC staining, FISH and CISH signals were performed
in a blinded manner.
IHC
A total of 27 (34%) tumours were defined as 0 or 1þ, 29 (37%)
tumours were defined as 2þ, and the remaining 23 (29%) tumours
were defined as 3þ (Table 1).
FISH
As a result of the material chosen for this study, FISH analysis was
necessarily successful in all cases. In all, 41 tumours were
determined as NAF, 11 tumours as LAF and 26 tumours as HAF
(Table 1).
CISH
CISH was successful in 75 of the 79 tumours (94.9%). The four
cases without any signal (WS) corresponded to four of the 22
tumours fixed in AFA. In these tumours, despite the use of a great
variation of pretreatment procedures, no signal was present in any
tumour cell. In all, 39 tumours were determined as NAC, nine as
LAC and 27 as HAC (Table 1).
Comparison of CISH and FISH results
Only 75 tumours were available for this comparison (Table 1).
When we compared all CISH amplifications (LACþHAC) to all
Figure 1 (A) CISH, only one or two signals are present in the nucleus of
tumour cells (NAC). (B) Same case analysed with FISH (NAF). Pink dots
correspond to HER2 probe and green dots correspond to centromere 17
probe. (C) CISH, six signals are present in the nucleus of tumour cells
(LAC). (D) Same case analysed with FISH (LAF) with a ratio of HER2 dots/
centromere 17 dots¼3. (E) CISH, large gene copy clusters are present in
the nucleus of tumour cells (HAC). (F) Same case analysed with FISH
(HAF).
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out of 75 (96%) tumours (Table 3). The kappa coefficient (k)
measuring agreement between the methods (0: no agreement, 1:
agreement) was 0.97 (Po10
 9), and if FISH was chosen as the gold
standard, the sensibility of CISH would be close to 97% with a
specificity of 95%. In nonproblematic IHC tumours (0, 1þ and
3þ), this agreement was found in 46 out of 47 (98%) cases
(k¼0.95 (Po10
 9), sensibility¼95% and specificity¼100%). On
the other hand, in problematic tumours (2þ), this agreement was
found in 26 out of 28 (92.8%) cases (k¼0.85 (Po5 10
 6),
sensibility¼100% and specificity¼85%). When we compared the
level of amplification determined with the two methods, an
agreement was found in 70 out of 75 (93.3%) with a k¼0.88
(Po10
 9).
Analysis of the cases with polysomy of chromosome 17
Centromeric probes of chromosome 17 were included in FISH
analyses in 61 of the 75 cases successfully analysed with CISH. The
result of the analysis of this centromere is summarised in Table 2.
Using a w
2 test, we found that polysomy was statically (Po0.005)
more frequently observed in IHC 2þ tumours (10 out of 16: 62.5%)
than in other situations (7 out of 45: 15.55%).
DISCUSSION
Since the FDA approved Herceptin
s for the treatment of
metastatic breast cancer (Pegram et al, 1998; Cobleigh et al,
1999; Roche and Ingle, 1999; Slamon et al, 2001), and in order to
determine whose patients might benefit from this new therapy,
there has been a need to evaluate precisely the HER2 status of
breast cancer specimens. The determination of this status will also
be important to choose the adjuvant strategy if clinical trials
including Herceptin
s as adjuvant therapy give a positive result
(Hortobagyi and Perez, 2001). Moreover, in the future, HER2
status may also help select patients for tyrosine kinase inhibitor
therapy (Moasser et al, 2001). Two major methods (IHC and FISH)
for the determination of this HER2 status have been developed all
around the world but there is no consensus up to now regarding
the best methods to determine this status (Thor, 2001). In two
recent different clinical trials, poor concordance was found
between local and central or reference IHC testing for HER2 (Paik
et al, 2002; Roche et al, 2002). This poor concordance being given,
the authors of these studies recommended that the HER2 status of
patients included in clinical trials should be done in large-volume
reference laboratories. These data also suggested an urgent need to
improve the quality control programme in laboratories that use
IHC testing (Fitzgibbons et al, 2000; Hoang et al, 2000; Ridolfi et al,
2000; Tubbs et al, 2001; Paik et al, 2002; Roche et al, 2002; Vogel
et al, 2002). In a previous study, we showed that FISH may be used
to obtain successfully a calibration of the in-house IHC technique
(Vincent-Salomon et al, 2003).
CISH, a hybridisation procedure using a staining of the probe
similar to IHC staining, has been previously proposed as an
alternative for FISH (Tanner et al, 2000). When compared with
FISH, CISH has been described as having several advantages
(Tanner et al, 2000; Zhao et al, 2002). It does not require an
expensive fluorescence microscope with multi-band-pass filters,
CISH staining is permanent and it does not need to be recorded
with an expensive CDD camera. Moreover, morphology is easier
analysed on CISH slides, particularly for distinguishing invasive
cancer cells and in situ components. Finally, pathologists are more
familiar with the IHC signal than with the FISH signal. The
advantages and disadvantages of these two hybridisation tech-
niques are summarised in Table 3.
In order to confirm the results of this study and to precise the
place of this technique in problematic IHC cases (2þ), we
performed a study on a group of 79 breast tumours that contained
an abnormal percentage (37%) of 2þ. Our study was also different
from the study published earlier because the breast tissue came
from different purveyor laboratories using different fixatives. CISH
procedures were successful in 95% of our cases, which is identical
to the results observed with FISH on paraffin sections (Lebeau et al,
2001) and very close to the results (98%) published with CISH in
an unselected group of tumours (Tanner et al, 2000). It may be
Table 1 HER2 gene amplification determined by FISH and CISH,
according to the overexpression of HER2 protein determined by IHC
IHC
0o r1 + 2 + 3 +
(N¼27) (N¼29) (N¼23)
FISH 27 NAF 14 NAF 11 LAF 4 HAF 1 NAF 22 HAF
CISH 25 NAC 12 NAC 8 LAC 4 HAC 1 NAC 20 HAC
2 WS 1 LAC 2 HAC 1 NAC
1H A C 1W S 1W S
NAF¼no amplification with FISH; LAF¼low level of amplification with FISH;
HAF¼high level of amplification with FISH; WS¼without any signal; NAC¼no
amplification with CISH; LAC¼low level of amplification with CISH; HAC¼high
level of amplification with CISH.
Table 2 Analysis of the cases with or without polysomy of chromosome 17
IHC
0o r1 + 2 + 3 +
N¼24 N¼16 N¼21
Normal chromosome 17 status N¼18 N¼6N ¼20
FISH 18 HAF 4 NAF 2 LAF 1 NAF 19 HAF
CISH 18 HAC 4 NAC 2 LAC 1 NAC 18
HAC
1N A C
Chromosome 17 polysomy N¼6N ¼10 N¼1
FISH 6 NAF 6 NAF 1 LAF 3 HAF 1 HAF
CISH 6 NAC 5 NAC 1 LAC 3 HAC 1 HAC
1 LAC
NAF¼no amplification with FISH; LAF¼low level of amplification with FISH; HAF¼high level of amplification with FISH;
WS¼without any signal; NAC¼no amplification with CISH; LAC¼low level of amplification with CISH; HAC¼high level
of amplification with CISH.
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for CISH, as CISH was successful in only 18 (82%) of the
22 tumours fixed in AFA and successful in all (100%) of the
tumours fixed in neutral-buffered formalin or Holland’s bouin.
We found a very good concordance between the CISH and FISH.
In terms of amplification, there was indeed an agreement
between CISH and FISH in 96% of the tumours, which is almost
the same as the agreement previously published (93.6%) (Tanner
et al, 2000). The agreement was a little higher (98%) for
nonproblematic (0, 1þ,3 þ) IHC cases than for problematic
(2þ) IHC tumours (93%). Owing to the small number (3%) of 2þ
cases in their study, Tanner et al did not notice this small
difference. In terms of sensitivity, when we compared the level of
amplification estimated by the two methods (no amplification, low
level and high level of amplification), we found that the results of
CISH analyses were very close to those given by FISH, with an
agreement in 93% of the tumours. According to Tanner et al
(2000), the discrepancy between CISH and FISH may be because of
a lower sensitivity of CISH. However, this explains only one
discordant case in our study, which was found to be amplified with
FISH but not with CISH. Other discrepancies may also be because
of differences in the sample materials or the thickness of the slides.
The most difficult situations with CISH are when 6–10 spots are
present in tumour cells. Double-colour FISH analyses may give
more information, particularly the ratio between HER2 signal and
the number of chromosome 17, and may separate the high
polysomy of chromosome 17 and the very low level of HER2
amplification. We found that polysomy of chromosome 17 is
statically more frequent in IHC 2þ tumours, but only one of our
discordant cases could probably be linked to this phenomenon. In
routine, these situations are very infrequent and it is not proved
that this distinction is relevant in terms of response to Herceptin
s
therapy. Clinical trials, including a large number of IHC 2þ
tumours with a low level of amplification, are needed to confirm
that the exact level of HER2 gene amplification is important for the
patient’s selection for specific therapy. Anyway, double-colour
staining CISH procedures, including HER2 and chromosome 17
probes, will soon be available. The results of these new procedures
would also have to be compared with the double-colour FISH
analysis.
Our study confirms that CISH may be an alternative to FISH for
the determination of HER2 gene status, particularly in laboratories
that are not equipped or trained from fluorescence analyses. In our
opinion, CISH is too expensive and too sophisticated to be an
alternative to IHC screening of all the breast tumours. However,
because of the good correlation between CISH and FISH, even in
ambiguous IHC results, we think that it may be used for the
determination of gene amplification status in IHC 2þ tumours.
Owing to the poor concordance between HER2 status established
in local laboratories in comparison to reference laboratories, we
also think that, in many laboratories, CISH may be an excellent
method to calibrate IHC procedures or, as a quality control test, to
check regularly that the IHC signal is in agreement with gene
status.
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